The challenges of clinical trials in fragile X syndrome

Rationale Advances in understanding the underlying mechanisms of conditions such as fragile X syndrome (FXS) and autism spectrum disorders have revealed heterogeneous populations. Recent trials of novel FXS therapies have highlighted several challenges including subpopulations with possibly differen...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Psychopharmacology Ročník 231; číslo 6; s. 1237 - 1250
Hlavní autori:	Jacquemont, Sébastien, Berry-Kravis, Elizabeth, Hagerman, Randi, von Raison, Florian, Gasparini, Fabrizio, Apostol, George, Ufer, Mike, Des Portes, Vincent, Gomez-Mancilla, Baltazar
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2014 Springer Springer Nature B.V Springer Verlag
Predmet:	Analysis Animals Autism Biomedical and Life Sciences Biomedicine Care and treatment Child Development Disorders, Pervasive - drug therapy Child Development Disorders, Pervasive - physiopathology Clinical trials Clinical Trials as Topic - methods Cognitive science Developmental disabilities Diagnosis Fragile X syndrome Fragile X Syndrome - diagnosis Fragile X Syndrome - drug therapy Fragile X Syndrome - genetics Fragile X Syndrome - physiopathology GABA Genetic aspects Genetic disorders Humans Methylation Neurosciences Pharmacology/Toxicology Phenotype Psychiatry Psychopharmacology Review FMRP Disease modification Mavoglurant GABA Fragile X syndrome mGluR5 Arbaclofen Autism spectrum disorder AFQ056
ISSN:	0033-3158, 1432-2072, 1432-2072
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!